History
Documents created during the development process.
Background information
-
-
Appendix A: Review decision paper considered by the Institute’s Guidance Executive
-
Appendix A: Decision paper considered by the Institute's Guidance Executive (PDF 73 KB)
-
Appendix A: Decision paper considered by the Institute's Guidance Executive
-
Appendix A: Decision paper considered by the Institute's Guidance Executive (PDF 73 KB)
-
-
Provisional matrix of stakeholders
-
-
Proposal paper presented to the Institute’s Guidance Executive
-
-
Acute coronary syndromes - glycoprotein IIb/IIIa inhibitors (review): proposal paper presented to the Institute's Guidance Executive
-
-
Acute coronary syndromes - glycoprotein IIb/IIIa inhibitors (review): provisional matrix of stakeholders
-
-
-
Assessment Report: Glycoprotein IIb/IIIa inhibitor guidance for acute coronary syndromes
-
-
Glycoprotein IIb/IIIa Modelling Report
-
-
-
Review decision - September 2005
-
-
Appendix A - Matrix of consultees and commentators.
-
Appendix A - Matrix of consultees and commentators. (PDF 41 KB)
-
-
Acute coronary syndromes
-
Final Appraisal Determination: The use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes
Appraisal Consultation Document: Glycoprotein IIb/IIIa Inhibitors
Assessment report: Glycoprotein IIb/IIIa Antagonists
Cost-effectiveness model: Glycoprotein Antagonists
A Systematic Review Update of the Clinical Effectiveness and Cost Effectiveness of Glycoprotein IIb/IIIa Antagonists
-
A Systematic Review Update of the Clinical Effectiveness and Cost Effectiveness of Glycoprotein IIb/IIIa Antagonists
-